After decades of limited progress, the development of novel anti-TB medicines was revitalised at the start of the 21st century through new initiatives and investments. This has resulted in innovations in treatment regimens thanks to new compounds becoming available and the re-purposing of existing drugs. However, progress has been relatively slow for a disease that, until the emergence of the COVID-19 pandemic, has remained the top infec- tious killer worldwide. Accelerated action is there- fore necessary to reach the ambitious target of ‘‘ending TB’’ set by the WHO within its new Global Strategy (2016–2030). Read Here.
top of page
Recent Posts
See AllThis week, the WHO recommended four new treatments for patients with MDR-TB. Three of the regimens were from the End TB trial, and one...
130
The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to...
290
Johnson and Johnson successfully applied for a patent extension on bedaquiline; however, in a big win for LMI countries, the company has...
200
bottom of page
Comments